Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jan:146:110464.
doi: 10.1016/j.mehy.2020.110464. Epub 2020 Dec 22.

Closing the portal to SARS-CoV-2 cellular entry: May open newer avenues…

Ridhima Sharma  1 , Rohan Magoon  2 , Brajesh Kaushal  3
Affiliations
Comment

Closing the portal to SARS-CoV-2 cellular entry: May open newer avenues…

Ridhima Sharma et al. Med Hypotheses. 2021 Jan.
No abstract available

Keywords: COVID-19; Camostat mesylate; Cellular entry; Nafamostat mesylate; SARS-CoV-2 pneumonia; Thrombosis; Transmembrane protease serine 2 (TMPRSS2).

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Comment on

References

    1. Kumar A., Narayan R.K., Kumari C., Faiq M.A., Kulandhasamy M., Kant K., Pareek V. SARS-CoV-2 cell entry receptor ACE2 mediated endothelial dysfunction leads to vascular thrombosis in COVID-19 patients. Med Hypotheses. 2020;145:110320. doi: 10.1016/j.mehy.2020.110320. - DOI - PMC - PubMed
    1. Magoon R., ItiShri, Kohli J.K., Kashav R. Inhaled milrinone for sick COVID-19 cohort: a pathophysiology driven hypothesis! Med Hypotheses. 2020:110441. doi: 10.1016/j.mehy.2020.110441. - DOI - PMC - PubMed
    1. Hofmann-Winkler H., Moerer O., Alt-Epping S., Bräuer A., Büttner B., Müller M. Camostat mesylate may reduce severity of Coronavirus disease 2019 sepsis: a first observation. Crit Care Explor. 2020;2(11):e0284. doi: 10.1097/CCE.0000000000000284. - DOI - PMC - PubMed
    1. Breining P., Frølund A.L., Højen J.F., Gunst J.D., Staerke N.B., Saedder E. Camostat mesylate against SARS‐CoV‐2 and COVID‐19—rationale, dosing and safety. Clin Pharmacol Toxicol. 2020 doi: 10.1111/bcpt.13533. - DOI - PubMed
    1. Asakura H., Ogawa H. Potential of heparin and nafamostat combination therapy for COVID‐19. J Thromb Haemost. 2020;18(6):1521–1522. doi: 10.1111/jth.14858. - DOI - PMC - PubMed

Substances